Answers are grounded in this paper and cite their sources.
Case series reveals genomic diversity in pediatric primary cutaneous anaplastic large cell lymphoma, indicating implications for treatment outcomes.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare pediatric CD30-positive T-cell lymphoproliferative disorder with an excellent prognosis, but its genomic drivers are poorly defined. We report three children with skin-limited disease demonstrating striking molecular heterogeneity, including NPM::ALK, NUP214::FRK, and a novel PICALM::JAK2 fusion not previously described in pcALCL. Clinical courses ranged from spontaneous regression to systemic therapy, yet all achieved durable complete remission without progression over 31-50 months. These findings highlight previously unrecognized genomic diversity and expand the molecular landscape of pediatric pcALCL.
No takes yet. Share an insight, caveat, or question.
Greenberger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: